BRPI0920498A2 - método de tratamento de uma condição em um sujeito - Google Patents

método de tratamento de uma condição em um sujeito

Info

Publication number
BRPI0920498A2
BRPI0920498A2 BRPI0920498A BRPI0920498A BRPI0920498A2 BR PI0920498 A2 BRPI0920498 A2 BR PI0920498A2 BR PI0920498 A BRPI0920498 A BR PI0920498A BR PI0920498 A BRPI0920498 A BR PI0920498A BR PI0920498 A2 BRPI0920498 A2 BR PI0920498A2
Authority
BR
Brazil
Prior art keywords
treating
subject
condition
Prior art date
Application number
BRPI0920498A
Other languages
English (en)
Inventor
B Manning Bog Amy
Ari Azhir Arasteh
Shulle Birgitt
A Lingwood Clifford
S Mcgrath Michael
J Langston William
Original Assignee
Neuraltus Pharmaceuticals Inc
Parkinson´S Inst
Hospital For Sick Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuraltus Pharmaceuticals Inc, Parkinson´S Inst, Hospital For Sick Children filed Critical Neuraltus Pharmaceuticals Inc
Publication of BRPI0920498A2 publication Critical patent/BRPI0920498A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0920498A 2008-11-14 2009-09-04 método de tratamento de uma condição em um sujeito BRPI0920498A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19924308P 2008-11-14 2008-11-14
PCT/US2009/056116 WO2010056413A2 (en) 2008-11-14 2009-09-04 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION

Publications (1)

Publication Number Publication Date
BRPI0920498A2 true BRPI0920498A2 (pt) 2019-09-24

Family

ID=42170611

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920498A BRPI0920498A2 (pt) 2008-11-14 2009-09-04 método de tratamento de uma condição em um sujeito

Country Status (9)

Country Link
US (2) US20120052053A1 (pt)
EP (1) EP2361089A4 (pt)
JP (2) JP2012508740A (pt)
CN (1) CN102245180A (pt)
AU (1) AU2009314447A1 (pt)
BR (1) BRPI0920498A2 (pt)
CA (1) CA2745451A1 (pt)
GB (1) GB2480159A (pt)
WO (1) WO2010056413A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2466912B (en) * 2007-11-29 2012-01-04 Hospital For Sick Children Compositions and methods for treating lysosomal disorders
US9265735B2 (en) * 2010-11-30 2016-02-23 New York University Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof
EP2533051A1 (en) * 2011-06-06 2012-12-12 Centogene GmbH Method for the diagnosis of Gaucher's disease
EP2739304A4 (en) * 2011-08-04 2015-06-03 Univ Ramot PARTICLES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
CN103120696A (zh) * 2011-11-18 2013-05-29 复旦大学 羊角衣酸在制备抗肿瘤药物中的应用
CN103120697B (zh) * 2011-11-18 2015-10-07 复旦大学 鳞片酸在制备抗肿瘤药物中的应用
CN104069263A (zh) * 2013-03-27 2014-10-01 中国科学院上海药物研究所 一种用于治疗阿尔茨海默病的制剂及其制备方法
WO2014162737A1 (ja) 2013-04-02 2014-10-09 学校法人同志社 タウ凝集阻害剤
CN105796579A (zh) * 2014-12-31 2016-07-27 中国科学院兰州化学物理研究所 抗老年性脑痴呆药物
US10702571B2 (en) 2015-12-03 2020-07-07 The University Of North Carolina At Pembroke Materials for cathepsin B enhancement and methods of use
CA3018745A1 (en) * 2016-03-25 2017-09-28 Genzyme Corporation Biomarkers of proteopathies and uses thereof
CA3018893A1 (en) * 2016-03-28 2017-10-05 Syneurx International (Taiwan) Corp. Compositions containing tannic acids and uses thereof
CN105748460B (zh) * 2016-04-07 2018-11-02 大连医科大学附属第二医院 一种治疗老年痴呆的药物
ES2650175B1 (es) * 2016-04-15 2019-02-04 Servicio Andaluz De Salud Tratamiento de enfermedades neurodegenerativas
US10064833B2 (en) 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
CN108143738A (zh) * 2016-12-02 2018-06-12 中国科学院大连化学物理研究所 一种治疗阿尔茨海默症的药物组合物及其制备和应用
CN107823198A (zh) * 2017-11-16 2018-03-23 黑龙江葆纳生物科技有限责任公司 北美圣草素在制备治疗阿尔茨海默病药物中的应用
KR20200097255A (ko) * 2017-12-07 2020-08-18 신유알엑스 인터내셔널 (타이완) 코포레이션 탄닌산 조성물을 제조하기 위한 개선된 풍부화 방법
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
WO2019169247A1 (en) * 2018-03-01 2019-09-06 The Johns Hopkins University DISCOVERY OF 2,6-DIMETHOXY-4-(5-PHENYL-4-THIOPHENE-2-YL-1H-IMIDAZOL-2-YL)-PHENOL (DPTIP) A SMALL MOLECULE INHIBITOR OF NEUTRAL SPHINGOMYELINASE 2 (nSMase-2) FOR THE TREATMENT OF NEURODEGENERATIVE AND ONCOLOGIC DISEASES
KR102102868B1 (ko) * 2019-05-14 2020-04-23 주식회사 노브메타헬스 고시페틴(Gossypetin)을 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
US11154531B2 (en) 2020-02-08 2021-10-26 Syneurx International (Taiwan) Corp. Compounds and pharmaceutical uses thereof
US10993958B1 (en) 2020-03-16 2021-05-04 William B. Coe Aldehyde functional monoterpenoids for the treatment of coronavirus infection
WO2021188575A1 (en) * 2020-03-16 2021-09-23 Coe William B Dietary supplement comprising aldehyde functional monoterpenoids
JP2023522753A (ja) 2020-04-23 2023-05-31 シニュークス インターナショナル（タイワン）コーポレイション 化合物及びその薬学的使用
WO2022104011A1 (en) * 2020-11-12 2022-05-19 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
CN112870250B (zh) * 2021-01-21 2022-08-12 广东盛普生命科技有限公司 防治器官纤维化的组合物及其应用与制剂
CN112704680B (zh) * 2021-01-21 2022-08-02 广东盛普生命科技有限公司 预防和/或治疗器官纤维化的组合物及其应用与制剂
WO2024026390A2 (en) * 2022-07-28 2024-02-01 Wylder Nation Foundation Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases
KR20240023004A (ko) * 2022-08-12 2024-02-20 포항공과대학교 산학협력단 고시페틴을 포함하는 지방간 개선용 조성물
CN115417789B (zh) * 2022-09-03 2023-08-04 郑州大学 一种治疗帕金森氏病的化合物、其制备方法以及复方药物组合物和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
JP2007500219A (ja) * 2003-05-16 2007-01-11 アンビット バイオサイエンシス コーポレーション 複素環化合物およびその使用法
KR20080033242A (ko) * 2005-06-08 2008-04-16 아미쿠스 세라퓨틱스, 인코포레이티드 리소좀 효소를 코딩하는 유전자의 돌연변이와 관련있는ｃｎｓ 질환의 치료 방법
WO2007003941A1 (en) * 2005-07-06 2007-01-11 Cambridge Enterprise Limited Modulation of autophagy by calpain inhibition
DE602007013648D1 (de) * 2006-05-24 2011-05-19 Amicus Therapeutics Inc Tartratsalz aus Isofagomin und Verwendungsverfahren dafür
KR101402554B1 (ko) * 2006-06-23 2014-06-19 아미쿠스 세라퓨틱스, 인코포레이티드 β-글루코세레브로시다제의 활성 증진에 의한 신경계 장애 치료 방법
EP2066323A2 (en) * 2006-09-12 2009-06-10 NeuroSearch AS Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein

Also Published As

Publication number Publication date
WO2010056413A2 (en) 2010-05-20
US20150044193A1 (en) 2015-02-12
CN102245180A (zh) 2011-11-16
EP2361089A1 (en) 2011-08-31
GB201108374D0 (en) 2011-06-29
AU2009314447A1 (en) 2010-05-20
GB2480159A (en) 2011-11-09
CA2745451A1 (en) 2010-05-20
US20120052053A1 (en) 2012-03-01
JP2012508740A (ja) 2012-04-12
JP2015127343A (ja) 2015-07-09
EP2361089A4 (en) 2012-08-22

Similar Documents

Publication Publication Date Title
BRPI0920498A2 (pt) método de tratamento de uma condição em um sujeito
IL212348A0 (en) Treatment method
BRPI0910854A2 (pt) métodos de tratamento
BRPI0919116A2 (pt) método
BRPI0910259A2 (pt) métodos de tratamento de inflamação
BRPI0920284A2 (pt) composição e método
FI20095369A0 (fi) Menetelmä ja väline jätteenkäsittelyssä
BRPI1013317A2 (pt) método de cimentação
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BRPI0917575A2 (pt) métodos de tratamento de talassemia
FI20095554A0 (fi) Menetelmä ja väline jätteenkäsittelyssä
EP2331564A4 (en) PROCESS FOR TREATMENT OF IGNITION
BR112013012485A2 (pt) método de tratamento com inibidor braf
BRPI0912559A2 (pt) método de tratar insuficiência cardíaca crônica
DK2313489T3 (da) Fremstillingsmetode
BRPI0919813A2 (pt) aparelho de exercício e método para operar aparelho de exercício
BRPI0911077A2 (pt) método para tratamento de biomassa
FI20085657A0 (fi) Valaisin ja ohjausmenetelmä
EP2350641A4 (en) Methods of Treatment
FI20085158A0 (fi) Laite ja menetelmä
BR112012005140A2 (pt) inibidores de hsl úteis no tratamento de diabetes
BRPI0916818A2 (pt) Método para tratamento de dentes sensíveis
BRPI1015216A2 (pt) método de tratar ou prevenir uma condição médica em um indivíduo.
BRPI0916597A2 (pt) Método
BRPI0907437A2 (pt) Método de tratamento da água

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.